Dr. Todd Hobbs
Vice President & Chief Medical Officer, Novo Nordisk, North America
Todd Hobbs, MD, is vice president and chief medical officer for Novo Nordisk in North America, where he leads the organization’s focus on the implications of diabetes for the patient, healthcare system and healthcare professionals.
Dr. Hobbs provides overall medical guidance to Novo Nordisk’s diabetes, cardiovascular, and obesity-related projects. He provides input into the clinical development and life-cycle management strategies for all approved products, as well as medical input into the R&D pipeline. He is involved with the optimization of relationships with top key opinion leaders and medical societies, and provides guidance to and participates in consultant advisory boards and key patient and professional association relationships.
Dr. Hobbs began his career at Novo Nordisk in 2004 as a field medical scientific director, then moving to the position of senior medical director, diabetes, in 2010. He led the Medical Affairs activities for all of Novo Nordisk’s current insulin products and devices, as well as supporting future insulin products through strategic and tactical activities.
He currently serves as a member of the board for the American Medical Group Association Foundation, the research foundation arm of the American Medical Group Association (AMGA).
Prior to working at Novo Nordisk, Dr. Hobbs had established a clinical practice based in Louisville, Kentucky, focusing on the intensive management of patients with diabetes of all ages, and served as chairman of the Medicine Department for a large Regional Medical Center in Kentucky. During this 10-year clinical career, he cared for more than 2,500 adults and children with diabetes, including outpatient and inpatient care, as well as intensive care.
Dr. Hobbs’ has a unique perspective on and personal dedication to the treatment of diabetes: his own experience with the disease began nearly 30 years ago when he was diagnosed with type 1 diabetes. His passion for defeating the disease intensified even more with the diagnosis of one of his sons with the same condition at the age of five.